|
1
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A, et al: The 2008 revision of the
World Health Organization (WHO) classification of myeloid neoplasms
and acute leukemia: Rationale and important changes. Blood.
114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Streiff MB, Smith B and Spivak JL: The
diagnosis and management of polycythemia vera in the era since the
Polycythemia Vera Study Group: A survey of American Society of
Hematology members' practice patterns. Blood. 99:1144–1149. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tefferi A: Polycythemia vera and essential
thrombocythemia: 2013 update on diagnosis, risk-stratification, and
management. Am J Hematol. 88:507–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gangat N, Caramazza D, Vaidya R, George G,
Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, et
al: DIPSS plus: A refined Dynamic International Prognostic Scoring
System for primary myelofibrosis that incorporates prognostic
information from karyotype, platelet count, and transfusion status.
J Clin Oncol. 29:392–397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rumi E, Pietra D, Ferretti V, Klampfl T,
Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC,
et al: Associazione Italiana per la Ricerca sul Cancro Gruppo
Italiano Malattie Mieloproliferative Investigators: JAK2 or CALR
mutation status defines subtypes of essential thrombocythemia with
substantially different clinical course and outcomes. Blood.
123:1544–1551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rotunno G, Mannarelli C, Guglielmelli P,
Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A and Vannucchi
AM: Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano
Malattie Mieloproliferative Investigators: Impact of calreticulin
mutations on clinical and hematological phenotype and outcome in
essential thrombocythemia. Blood. 123:1552–1555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nangalia J, Massie CE, Baxter EJ, Nice FL,
Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al:
Somatic CALR mutations in myeloproliferative neoplasms with
nonmutated JAK2. N Engl J Med. 369:2391–2405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Klampfl T, Gisslinger H, Harutyunyan AS,
Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B,
Pietra D, et al: Somatic mutations of calreticulin in
myeloproliferative neoplasms. N Engl J Med. 369:2379–2390. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of
tumours of haematopoietic and lymphoid tissues. World Health
Organization (4th). (Lyon). IARC Press. 2008.
|
|
11
|
Tanaka R, Kuroda J, Stevenson W, Ashihara
E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E,
Takeuchix M, et al: Fully automated and super-rapid system for the
detection of JAK2V617F mutation. Leuk Res. 32:1462–1467. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchioli R, Finazzi G, Landolfi R, Kutti
J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G and
Barbui T: Vascular and neoplastic risk in a large cohort of
patients with polycythemia vera. J Clin Oncol. 23:2224–2232. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Passamonti F, Cervantes F, Vannucchi AM,
Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella
M, Maffioli M, et al: A dynamic prognostic model to predict
survival in primary myelofibrosis: A study by the IWG-MRT
(International Working Group for Myeloproliferative Neoplasms
Research and Treatment). Blood. 115:1703–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hussein K, Pardanani AD, Van Dyke DL,
Hanson CA and Tefferi A: International Prognostic Scoring
System-independent cytogenetic risk categorization in primary
myelofibrosis. Blood. 115:496–499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn
A, Keating MJ, Thomas DA, Pierce S, Kantarjian H and Verstovsek S:
The role of cytogenetic abnormalities as a prognostic marker in
primary myelofibrosis: Applicability at the time of diagnosis and
later during disease course. Blood. 113:4171–4178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carobbio A, Thiele J, Passamonti F, Rumi
E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM,
Antonioli E, et al: Risk factors for arterial and venous thrombosis
in WHO-defined essential thrombocythemia: An international study of
891 patients. Blood. 117:5857–5859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koppikar P and Levine RL: JAK2 and MPL
mutations in myeloproliferative neoplasms. Acta Haematol.
119:218–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Levine RL and Gilliland DG:
Myeloproliferative disorders. Blood. 112:2190–2198. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thoennissen NH, Krug UO, Lee DH, Kawamata
N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato
M, et al: Prevalence and prognostic impact of allelic imbalances
associated with leukemic transformation of Philadelphia
chromosome-negative myeloproliferative neoplasms. Blood.
115:2882–2890. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cervantes F, Passamonti F and Barosi G:
Life expectancy and prognostic factors in the classic
BCR/ABL-negative myeloproliferative disorders. Leukemia.
22:905–914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scott LM, Tong W, Levine RL, Scott MA,
Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison
CN, et al: JAK2 exon 12 mutations in polycythemia vera and
idiopathic erythrocytosis. N Engl J Med. 356:459–468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
